Tekla Life Sciences Stock Buy Hold or Sell Recommendation
HQL Stock | USD 13.12 0.03 0.23% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Tekla Life Sciences is 'Strong Hold'. Macroaxis provides Tekla Life buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding HQL positions. The advice algorithm takes into account all of Tekla Life's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Tekla Life's buy or sell advice are summarized below:
Real Value 13.26 | Hype Value 13.12 | Market Value 13.12 | Naive Value 13.02 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Tekla Life Sciences given historical horizon and risk tolerance towards Tekla Life. When Macroaxis issues a 'buy' or 'sell' recommendation for Tekla Life Sciences, the advice is generated through an automated system that utilizes algorithms and statistical models.
Tekla |
Execute Tekla Life Buy or Sell Advice
The Tekla recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Tekla Life Sciences. Macroaxis does not own or have any residual interests in Tekla Life Sciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Tekla Life's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Tekla Life Trading Alerts and Improvement Suggestions
Tekla Life Sciences generated a negative expected return over the last 90 days | |
Tekla Life Sciences has high likelihood to experience some financial distress in the next 2 years | |
Tekla Life Sciences has about 292.4 K in cash with (12.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
On 28th of March 2024 Tekla Life paid $ 0.39 per share dividend to its current shareholders | |
Latest headline from MacroaxisInsider: Acquisition by Saba Capital Management, L.p. of 48203 shares of Tekla Life at 13.15 subject to Rule 16b-3 |
Tekla Life Returns Distribution Density
The distribution of Tekla Life's historical returns is an attempt to chart the uncertainty of Tekla Life's future price movements. The chart of the probability distribution of Tekla Life daily returns describes the distribution of returns around its average expected value. We use Tekla Life Sciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Tekla Life returns is essential to provide solid investment advice for Tekla Life.
Mean Return | -0.04 | Value At Risk | -1.44 | Potential Upside | 1.36 | Standard Deviation | 0.85 |
Return Density |
Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Tekla Life historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Tekla Life Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Tekla Life or Capital Markets sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Tekla Life's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Tekla stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.12 | |
β | Beta against NYSE Composite | 0.81 | |
σ | Overall volatility | 0.85 | |
Ir | Information ratio | -0.16 |
Tekla Life Volatility Alert
Tekla Life Sciences exhibits very low volatility with skewness of -0.04 and kurtosis of -0.03. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Tekla Life's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Tekla Life's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Tekla Life Fundamentals Vs Peers
Comparing Tekla Life's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Tekla Life's direct or indirect competition across all of the common fundamentals between Tekla Life and the related equities. This way, we can detect undervalued stocks with similar characteristics as Tekla Life or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Tekla Life's fundamental indicators could also be used in its relative valuation, which is a method of valuing Tekla Life by comparing valuation metrics with those of similar companies.
Better Than Average | Worse Than Average | Compare Tekla Life to competition |
Fundamentals | Tekla Life | Peer Average |
Return On Equity | 0.0128 | -0.31 |
Return On Asset | -0.0032 | -0.14 |
Profit Margin | 1.56 % | (1.27) % |
Operating Margin | (0.49) % | (5.51) % |
Current Valuation | 354.02 M | 16.62 B |
Shares Outstanding | 27.35 M | 571.82 M |
Shares Owned By Institutions | 36.04 % | 39.21 % |
Number Of Shares Shorted | 21.32 K | 4.71 M |
Price To Earning | 2.84 X | 28.72 X |
Price To Book | 0.87 X | 9.51 X |
Price To Sales | 99.22 X | 11.42 X |
Revenue | 23.52 M | 9.43 B |
Gross Profit | 3.02 M | 27.38 B |
EBITDA | 22.35 M | 3.9 B |
Net Income | 22.35 M | 570.98 M |
Cash And Equivalents | 292.4 K | 2.7 B |
Cash Per Share | 0.01 X | 5.01 X |
Debt To Equity | 0.02 % | 48.70 % |
Current Ratio | 1.34 X | 2.16 X |
Book Value Per Share | 16.12 X | 1.93 K |
Cash Flow From Operations | (12.8 M) | 971.22 M |
Short Ratio | 0.34 X | 4.00 X |
Earnings Per Share | 0.79 X | 3.12 X |
Beta | 0.72 | -0.15 |
Market Capitalization | 359.66 M | 19.03 B |
Total Asset | 402.6 M | 29.47 B |
Retained Earnings | (1.48 M) | 9.33 B |
Annual Yield | 0.10 % | |
Five Year Return | 8.83 % | |
Net Asset | 402.6 M | |
Last Dividend Paid | 1.3 |
Note: Acquisition by Reit Todd of 1000 shares of Tekla Life at 13.798 subject to Rule 16b-3 [view details]
Tekla Life Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Tekla . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Tekla Life Buy or Sell Advice
When is the right time to buy or sell Tekla Life Sciences? Buying financial instruments such as Tekla Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.2021 | 2023 | 2024 (projected) | Total Stockholder Equity | 397.9M | 462.2M | 332.0M | Total Current Liabilities | 5.1M | 5.9M | 3.2M |
Use Investing Ideas to Build Portfolios
In addition to having Tekla Life in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Petroleum and Natural Gas Thematic Idea Now
Petroleum and Natural Gas
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Petroleum and Natural Gas theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Petroleum and Natural Gas Theme or any other thematic opportunities.
View All Next | Launch |
Check out Tekla Life Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Tekla Stock analysis
When running Tekla Life's price analysis, check to measure Tekla Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tekla Life is operating at the current time. Most of Tekla Life's value examination focuses on studying past and present price action to predict the probability of Tekla Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tekla Life's price. Additionally, you may evaluate how the addition of Tekla Life to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
CEOs Directory Screen CEOs from public companies around the world | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Tekla Life's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Dividend Share 1.3 | Earnings Share 0.79 | Revenue Per Share 0.134 | Quarterly Revenue Growth 0.344 |
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.